1167 Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.63 |
| 52 Week High | HK$4.43 |
| 52 Week Low | HK$1.38 |
| Beta | 0.54 |
| 11 Month Change | -11.89% |
| 3 Month Change | 7.24% |
| 1 Year Change | -62.27% |
| 33 Year Change | -90.01% |
| 5 Year Change | n/a |
| Change since IPO | -88.70% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31
Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Shareholder Returns
| 1167 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.8% | 1.5% | 0.4% |
| 1Y | -62.3% | -11.2% | 12.0% |
Return vs Industry: 1167 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 1167 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 1167 volatility | |
|---|---|
| 1167 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1167 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 298 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| 1167 fundamental statistics | |
|---|---|
| Market cap | HK$1.29b |
| Earnings (TTM) | -HK$388.97m |
| Revenue (TTM) | HK$24.92m |
51.6x
P/S Ratio-3.3x
P/E RatioIs 1167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1167 income statement (TTM) | |
|---|---|
| Revenue | CN¥23.19m |
| Cost of Revenue | CN¥22.38m |
| Gross Profit | CN¥801.00k |
| Other Expenses | CN¥362.69m |
| Earnings | -CN¥361.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 3.45% |
| Net Profit Margin | -1,560.88% |
| Debt/Equity Ratio | 7.0% |
How did 1167 perform over the long term?
See historical performance and comparison